Skip to main content
. 2019 Jul 22;4(4):e000532. doi: 10.1136/esmoopen-2019-000532

Table 3.

Tumour response to treatment (RECIST)

HRG low
(N=5)
HRG high
(N=7)
All patients
(N=12)
Objective response rate, N (%) 0 3 (42.9) 3 (25.0)
Disease control rate, N (%) 4 (80.0) 7 (100) 11 (91.7)
PFS, median (95% CI), days 100 (38, 196) 122 (65, 217) 122 (81, 217)

HRG, heregulin;PFS, progression-free survival; RECIST, response evaluation criteria in solid tumours.